Maintain ABBV at 3-4% portfolio cap; HOLD and collect 2.64% dividend while awaiting Q3 2026 earnings
HOLD is the correct synthesis because the bull case wins the fundamental debate (Q2 confirms post-Humira transition complete, +10.2% revenue acceleration is secular trend, 16x P/E with PEG sub-1, Dividend King franchise with $17B FCF and 1.53x coverage) while the bear case wins the timing debate (+16.3% above 200 SMA at 90th+ percentile, RSI divergence, price 1.9% from upper Bollinger, symmetric near-term risk-reward); at $264 these two arguments cancel out. Street consensus PT of $279 implies only ~6% upside. Position cap at 3-4% respects SKYRIZI/Rinvoq concentration risk (Trefis September 17 flag). Do not add at 52-week highs; let Q3 earnings resolve the SKYRIZI binary before committing new capital.
| Position | Action |
|---|---|
| Price at $258 (first scale-in zone) | Buy 25% of target position |
| Price at $254 (50 SMA support) | Buy additional 50% of target position |
| Price at $250 (final scale-in zone) | Buy remaining 25% of target position |
| Price below $245 | Hard stop - exit all positions |
| Price at $268-272 (upper Bollinger band confluence) | Trim 10-20% into rallies |
| Elevated IV; price at $270-275 | Sell covered calls (2-3 month expiry) to generate ~1-2% option premium |
ABBV is a quality compounder with accelerating revenue growth, expanding margins, and a multi-engine pipeline that is actively dismantling concentration risk while trading at an anomalously cheap forward valuation relative to its growth profile and dividend strength.
| Indicator | Value | Signal |
|---|---|---|
| Close | $264.02 | bullish |
| 10 EMA | $259.88 | bullish |
| 50 SMA | $254.93 | bullish |
| 200 SMA | $227.09 | bullish |
| MACD | 2.01 | bullish |
| MACD Signal | 1.67 | bullish |
| MACD Histogram | +0.34 | bullish |
| RSI (14) | 59.09 | neutral |
| ATR (14) | $5.60 | neutral |
| Bollinger Middle | $259.58 | bullish |
| Bollinger Upper | $268.93 | neutral |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Price reaches $254 (50 SMA)
Then: Add 50% position
EV: +14% to Wolfe $300 PT; +37% to TIKR $361 mid-case
ABBV is exhibiting classic late-cycle distribution characteristics—priced for perfection with Q1/Q2 2026 EPS volatility, 50% operating income collapse peak-to-trough, EV/EBITDA at 23.4x, FCF yield below S&P 500, negative stockholders' equity, bearish RSI divergence, and resistance at $266-270—making the risk-reward asymmetrically bearish and a pullback to $230-240 the more attractive entry point.
· concedes: Underlying immunology business has real franchise value with SKYRIZI showing strong >20% YoY growth in the near term; FCF generation is substantial at $17.8B annually; Dividend growth trajectory is intact; Beta of 0.28 does provide some downside cushion in market selloffs; Q2 2026 operating margin of 39.6% demonstrates business model efficiency when charges are normalized
→ vs conservative: Stock being +16.3% above the 200 SMA at the 90th+ percentile is not a sell signal; it confirms the structural uptrend and price is simply above lagging moving averages. Mean reversion trades die in front of secular compounding stories.
→ vs conservative: SKYRIZI/Rinvoq concentration risk is a stale 2024 narrative; Q2 2026 already showed 10.2% YoY revenue growth with 39.6% operating margins and multi-engine diversification including apogee for immunology, 74% myeloma response rate, and neuroscience transformation.
→ vs conservative: The 'rates are rising so avoid dividend stocks' heuristic is backwards; late-cycle defensive names with growing dividends get re-rated higher when growth slows, not lower.
→ vs neutral: Fixated on near-term 1:1 risk-reward at $264; ignores 37% upside to TIKR mid-case of $361 and 14% to Wolfe target of $300 over the holding horizon. Wrong framework—should be compounding analysis, not 30-day momentum.
→ vs neutral: Waiting for $254, $258, $250 scale-in zones is hope not strategy; chasing 3% lower after watching the stock ride the 10 EMA higher for weeks while a fresh MACD cross and Wolfe upgrade are still being absorbed by the Street is counterproductive.
| Bollinger Lower | $250.22 | neutral |
Support: 259.88 · 254.93 · 259.58 · 250.22 · 227.09 | Resistance: 268.93 · 266 · 270
ABBV exhibits a classic bullish three-tier moving average stack (price > 10 EMA > 50 SMA > 200 SMA, all rising), confirming an unambiguously bullish structural trend. Momentum has recovered from a significant early-September drawdown (RSI dropped to 41.79 on 2026-09-08) and is now reaccelerating with a fresh MACD bullish crossover; the mild RSI bearish divergence versus the August price high ($265.97-$267) is a caution flag warranting tight stops but not yet a reversal trigger. Volatility compression (ATR fell from $6.99 to $5.60) and price walking the upper Bollinger band ($268.93) favor trend continuation, with primary entry zones at $254-$260 and stop below $254 (50 SMA break).
Market Cap
$466.55 B
Share Price (Implied)
~$264
52-Week High
$267.47
52-Week Low
$190.75
50-Day MA
$254.84
200-Day MA
$229.23
Beta
0.281
P/E (TTM)
74.58
Forward P/E
16.23
PEG Ratio
0.54
P/B
-78.60
Dividend Yield
2.64%
EPS (TTM)
$3.54
Forward EPS
$16.27
Revenue FY2025
$61,160 M
Gross Profit FY2025
$42,956 M
Operating Income FY2025
$15,075 M
Net Income FY2025
$4,226 M
Diluted EPS FY2025
$2.36
Normalized EBITDA FY2025
$22,703 M
Special/Unusual Charges FY2025
$5,074 M
Intangible Amortization 2025
~$7.4B
R&D FY2025
$9,096 M
SG&A FY2025
$14,010 M
Q2 2026 Revenue
$16.99 B
Q2 2026 Operating Income
$6.72 B
Q2 2026 Net Income
$3.61 B
Q2 2026 Diluted EPS
$2.03
Q2 2026 EBITDA
$6.91 B
Q1 2026 Diluted EPS
$0.39
Cash & Equivalents Q2 2026
$6,569 M
Receivables Q2 2026
$13,824 M
Inventory Q2 2026
$5,127 M
Goodwill Q2 2026
$35,519 M
Other Intangibles Q2 2026
$49,139 M
Total Assets Q2 2026
$135,115 M
Total Debt Q2 2026
$70,822 M
Net Debt Q2 2026
$64,253 M
Stockholders' Equity Q2 2026
($5,935) M
Working Capital Q2 2026
($7,973) M
Net Debt / EBITDA
~3.4x
TTM FCF
$16.87 B
FCF FY2025
$17,816 M
Operating Cash Flow FY2025
$19,030 M
CapEx FY2025
($1,214) M
Dividends Paid FY2025
($11,657) M
Dividend Coverage (FCF/Div) FY2025
1.53x
Q2 2026 FCF
$3.11 B
Q2 2026 OCF
$3.44 B
Treasury Stock Q2 2026
$10.6 B
TTM Gross Margin
~72.8%
Strengths
Concerns
AbbVie is a mega-cap healthcare company with a market cap of $466.55B, trading near its 52-week high with a forward P/E of 16.23x on normalized EPS of $16.27, offering a 2.64% dividend yield with a PEG ratio of 0.54. The company demonstrated a Q2 2026 breakout with revenue of $16.99B (+10.2% YoY) and operating margin of 39.6%, driven by the Skyrizi/Rinvoq franchise ramp following Humira biosimilar erosion, while GAAP earnings remain depressed by ~$5.1B in special charges and ~$7.4B in intangible amortization. The balance sheet shows elevated leverage of ~3.4x Net Debt/EBITDA and negative stockholders' equity of ($5.9B), though free cash flow of ~$17.8B annually provides robust coverage of the dividend and debt service.
Macro: Fed hiking cycle fully priced in for 2026: Polymarket shows 84% probability of another rate hike, 62% probability of two hikes (+34.5pp WoW — sharp hawkish repricing), and 95% probability of zero cuts. The cut narrative is dead for 2026 (all '9, 10, 11, 12+ cuts' markets sit at 0%). Recession odds remain low at 10% for US by end-2026. Long-end easing (10Y yields) and oil at ~$100 suggest growth-softening-but-not-contracting scenario. Barrons noted 'stocks are loving the Fed's rate hike,' reframing hikes as growth resilience rather than policy mistake. This 'soft-landing with hawkish lean' historically supports quality compounders with high dividend yields like ABBV (~3.4% yield vs. 2.3% sector average).